Accelerating Biopharmaceutical Development
The Pfenex Expression Technology platform uniquely positions Pfenex to serve a wide range of markets and fulfill an unmet need for rapid reliable protein production and development. The Pfenex product pipeline currently contains nine biosimilar proteins in development. The 2012 global biologics market represented over $160 billion in product sales with virtually the entire market comprised of branded innovator products. Pfenex believes the emerging biosimilar market will be significant due to the large number of blockbuster products losing patent protection in the next several years, abbreviated regulatory pathways for the approval of biosimilars and a mandate for lower drug costs by governments and private payors.